PMID- 16019538
OWN - NLM
STAT- MEDLINE
DCOM- 20080729
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 46
IP  - 6
DP  - 2005 Jun
TI  - Lamivudine treatment in a patient with hepatitis B virus reactivation after 
      allogenic peripheral bone marrow transplantation.
PG  - 915-7
AB  - We report the case of a 52-year-old woman with hepatitis B virus (HBV) 
      reactivation during treatment for chronic graft vs. host disease (GVHD) after 
      peripheral bone marrow transplantation (PBSCT) to treat chronic myelocytic 
      leukemia. She was given cyclosporine and prednisolone orally to treat chronic 
      GVHD after PBSCT. Liver dysfunction first developed 25 months after 
      transplantation with the appearance of hepatitis B s antigen (HBsAg), hepatitis B 
      e antigen (HBeAg), and elevation of HBV-DNA up to 4.5 log copies/ml. 
      Retrospective examination of her serum before PBSCT proved negative for HBsAg and 
      HBeAg, and positive for anti-HBsAg, anti-HBeAg, anti-hepatitis B core antigen, 
      and HBV-DNA (2.7 log copies/ml), showing that she was in a state of occult HBV 
      infection. Nucleotide sequences of the HBV genome obtained from her serum showed 
      no core promoter mutations at nt 1762 and 1764 and no pre-core mutation at nt 
      1896. Polymerase chain reaction-restriction fragment length polymorphism showed 
      that she was infected with HBV genotype B. The administration of lamivudine, a 
      nucleoside analog, improved her liver function and reduced HBV-DNA replication. 
      We conclude that antiviral agents, such as lamivudine, are effective for treating 
      hepatitis B reactivation during immunosuppressive treatment, such as for GVHD. 
      The administration of a nucleoside analog before transplantation should also be 
      considered in the light of HBV genotypes and mutations, even if HBsAg was 
      negative and the viral load was low before transplantation.
FAU - Imamura, Takaaki
AU  - Imamura T
AD  - Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba 
      University, Japan. Taimamura@aol.com
FAU - Yokosuka, Osamu
AU  - Yokosuka O
FAU - Chiba, Tetsuhiro
AU  - Chiba T
FAU - Kanda, Tatso
AU  - Kanda T
FAU - Kojima, Hiroshige
AU  - Kojima H
FAU - Fukai, Kenichi
AU  - Fukai K
FAU - Imazeki, Fumio
AU  - Imazeki F
FAU - Nishimura, Miki
AU  - Nishimura M
FAU - Saito, Yasushi
AU  - Saito Y
FAU - Saisho, Hiromitsu
AU  - Saisho H
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antigens, Viral)
RN  - 0 (Antiviral Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - 2T8Q726O95 (Lamivudine)
SB  - IM
MH  - Antigens, Viral/chemistry
MH  - Antiviral Agents/therapeutic use
MH  - Bone Marrow Transplantation/adverse effects/*methods
MH  - DNA Replication
MH  - Female
MH  - Graft vs Host Disease
MH  - Hepatitis B/complications/*drug therapy
MH  - Hepatitis B virus/*metabolism
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Lamivudine/*therapeutic use
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications/*drug 
      therapy/virology
MH  - Liver/metabolism
MH  - Middle Aged
MH  - Mutation
EDAT- 2005/07/16 09:00
MHDA- 2008/07/30 09:00
CRDT- 2005/07/16 09:00
PHST- 2005/07/16 09:00 [pubmed]
PHST- 2008/07/30 09:00 [medline]
PHST- 2005/07/16 09:00 [entrez]
AID - W34NJ065858GP575 [pii]
AID - 10.1080/10428190500051091 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2005 Jun;46(6):915-7. doi: 10.1080/10428190500051091.